Order Test

November 27, 2023

Mindera Health ™ Announces Commercial Relocation

November 6, 2023

Mindera Health ™ announces the signing of a commercial agreement with Occum Health for Mind.Px ™

October 23, 2023

Mindera Inc. Signs Provider Contract with Provider Network Contigo Health ConfigureNet(™)

October 16, 2023

Mindera Health™ Announces Issuance of Additional International Patent Coverage for Dermal Biomarker Patch Platform

October 10, 2023

Mindera Health™ Announces Contract With General Services Administration®

October 3, 2023

Mindera Health™ Signs Contract with Nationwide Provider Network MediNcrease™

May 11, 2023

Mindera Health™ Announces Change to Executive Leadership Team

April 10, 2023

Mindera Health™ Announces Coverage with Evidence Project with Highmark, Inc. to Advance Moderate-to-Severe Psoriasis Patient Care and Reduce Specialty Drug Spending

March 14, 2023

Mindera Health™ Appoints Linh H. Le as Chief Financial Officer and Chief Operating Officer

December 12, 2022

Mindera Health™ Closes Upsized $20M Series A-3 Financing

October 20, 2022

Interim Results of MATCH Study Demonstrate Improved Decision Making and Clinical Outcomes When Using Mind.Px™ to Determine Biologic Drug Class for Psoriasis Patients

July 26, 2022

Mindera Health™ announces publication of a consensus panel opinion that positive results from the MATCH Study would prove clinical utility for precision medicine test Mind.Px™

April 28, 2022

Mindera Health™ Launches Pilot with National Health Insurance Company to Improve Management of Moderate-To-Severe Psoriasis Patients Through Precision Medicine

March 1, 2022

Mindera Health™ Appoints Deborah L. Rice-Johnson to its Board of Directors

January 4, 2022

Mindera Health™ and WellDyne announce a definitive agreement to improve management of moderate-to-severe psoriasis patients

November 16, 2021

Mindera Health™ announces publication of positive results from STAMP-1 and STAMP-2 studies

October 21, 2021

Mindera Health™ announces first patient enrolled in the MATCH Study; a clinical utility evaluation of the impact of Mind.Px™ on response rates of psoriasis patients who are prescribed biologics

October 5, 2021

Mindera Corporation Shifts Name to Mindera Health to Sharpen Focus on Its Personalized Medicine Platform

August 2, 2021

Dermatology Industry Veteran Ann Deren-Lewis Joins Mindera as Chief Commercial Officer

July 26, 2021

Mindera Survey Confirms the Impact of Physician Trial-and-Error Behavior on Psoriasis Biologic Treatment

July 19, 2021

Mindera ™ announces publication of an economic evaluation of precision medicine testing for the treatment of psoriasis

May 11, 2021

Mindera Raises Over $12M Series A-2 Financing

May 6, 2021

Mindera™ Honored as Winner in 2021 MedTech Breakthrough Awards Program, Best New Technology Solution – Dermatology

January 25, 2021

Mindera wins Prestigious Terra2 Skin Health Innovations Competition at 2021 Winter Clinical Dermatology Conference

January 12, 2021

Mindera Selected as Finalist in Terra2 Solutions Skin Health Innovation Competition at Winter Clinical Dermatology Conference

January 6, 2021

Mindera to Present Precision Medicine Test for Psoriasis Biologics at Dermatology Summit 2021

August 11, 2020

Mindera Announces CLIA Certification Achieved by its Diagnostics Laboratory

July 27, 2020

Mindera Corporation Announces Appointment of George W. Mahaffey as President and Chief Executive Officer

November 14, 2019

Mindera Corporation Raises $5.3M Series A to Commercialize Psoriasis Biologic Responsiveness Test